Covid-19: Centre's expert panel allows clinical trials for third dose of Covaxin

Covid-19: Centre's expert panel allows clinical trials for third dose of Covaxin The firm presented amendments in the approved Phase 2 clinical trial protocol for administration of booster dose after six months after second dose. After detailed deliberation, the committee recommended that the firm should conduct the booster dose study only in 6 mcg cohort and also should follow up the subjects at least for six months after the third dose, the SEC said. https://ift.tt/eA8V8J